Targeting cardiovascular risk: The impact of age, gender and compliance to treatment

Current Medical Research and Opinion

Volumn 28, Issue 9, 2012, Pages 1415-1419

  Kostapanos, Michael S ^a   Elisaf, Moses S ^a   Mikhailidis, Dimitri P ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amlodipine; Atorvastatin; Cardiovascular risk; Compliance; Single pill; Statin

Indexed keywords

AMLODIPINE; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; URIC ACID;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DEMENTIA; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FUNCTION; LIVER FUNCTION TEST; NONALCOHOLIC FATTY LIVER; PATIENT COMPLIANCE; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; URIC ACID BLOOD LEVEL; URINARY EXCRETION; VASCULAR DISEASE;

AGE FACTORS; BLOOD PRESSURE; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; SEX FACTORS;

EID: 84866684691     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.715518     Document Type: Review

References (49)

1. Feldman R FJ, Howes L, Jenssen T, et al. Impact of age and gender on blood pressure and low-density lipoprotein cholesterol reduction: results of a pooled analysis. Curr Med Res Opin 2012; July 19 (Epub ahead of print)
2. Ansell BJ. Evidence for a combined approach to the management of hypertension and dyslipidemia. Am J Hypertens 2005;18:1249-57
3. Daskalopoulou SS, Doonan RJ, Mikhailidis DP. Undertreatment of hypercho-lesterolemia. Curr Med Res Opin 2010;26:439-43
4. Levine AP, Mikhailidis DP, Moross T, et al. Achieving vascular risk factor targets: a survey of a London general practice. Angiology 2008;59:36-46
5. Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006;98:204-8
6. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151:185-91
7. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
8. Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf 2008;7:717-25
9. Karagiannis A, Hatzitolios AI, Athyros VG, et al. Implementation of guidelines for the management of arterial hypertension. The IMPULSION study. Open Cardiovasc Med J 2009;3:26-34
10. Perreault S, Dragomir A, Roy L, et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010;69:74-84
11. Sung SK, Lee SG, Lee KS, et al. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther 2009;31:1309-20
12. Jin J, Sklar GE, Min Sen Oh V, et al. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008;4:269-86
13. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002;24:302-16
14. Hatzitolios AI, Athyros VG, Karagiannis A, et al. Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol 2009;134:322-9
15. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52
16. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673-81
17. Hussein MA, Chapman RH, Benner JS, et al. Does a single-pill antihyperten-sive/lipid-lowering regimen improve adherence in US managed care enro-lees? A non-randomized, observational, retrospective study. Am J Cardiovasc Drugs 2010;10:193-202
18. Kagansky N, Levy S, Berner Y, et al. Cholesterol lowering in the older population: time for reassessment? Q J Med 2001;94:457-63
19. Kalantzi KJ, Milionis HJ, Mikhailidis DP, et al. Lipid lowering therapy in the elderly: is there a benefit? Curr Pharm Des 2006;12:3945-60
20. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
21. Gotto Jr AM, Statin therapy and the elderly: SAGE advice? Circulation 2007;115:681-3
22. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
23. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
24. Kostapanos MS, Elisaf MS. JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World J Cardiol 2011;3:207-14
25. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488-96
26. Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis 2012;21:436-44
27. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005;65:1388-94
28. McGuinness B, O'Hare J, Craig D, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010;CD007514
29. Pasternak RC, Smith Jr. SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002;106:1024-8
30. Kostapanos MS, Athyros VG, Karagiannis A, et al. Therapeutic options for statin-intolerant patients. Curr Med Res Opin 2012;28:345-9
31. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105
32. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J Cardiometab Syndr 2009;4:E4-9
33. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
34. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorva-statin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
35. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9
36. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009;54:810-9
37. Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011;9:698-705
38. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
39. Kostapanos MS, Katsiki N, Elisaf MS, et al. Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL C) lowering enough? Curr Vasc Pharmacol 2012;10:173-7
40. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
41. Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006;40:745-52
42. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40(Suppl 1):S5-10
43. Kostapanos MS, Milionis HJ, Agouridis AD, et al. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009;63:1308-13
44. Kostapanos MS, Liamis GL, Milionis HJ, et al. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612-31
45. Bairey Merz CN, Olson MB, Johnson BD, et al. Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: the Women's Ischemia Syndrome Evaluation (WISE). Am J Med 2002;113:723-7
46. Ding EL, Powe NR, Manson JE, et al. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med 2007;167:905-12
47. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291:2243-52
48. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069-77
49. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Curr Med Res Opin 2008;24:1593-9